Objectives: To define the role of single or serial measurement of endothelin 1 (ET-1) for prognostication beyond traditional and modern markers of risk in heart failure (HF).
Results: Elevated ET-1 was associated with worse HF, lower right ventricular function, higher pulmonary pressure, and higher left atrial volume index despite similar left ventricular function. ET-1 correlated with angiotensinconverting enzyme inhibitor use. A model containing traditional risk factors, ET-1, NT-proBNP, hsTnI, and sST2 best predicted cardiovascular events, and ET-1 improved reclassification. In an adjusted time-integrated model, percent time spent with ET-1 of 5.90 pg/mL or less was predictive of fewer cardiovascular events (odds ratio, 0.75; 95% confidence interval, 0.62-0.91). ET-1 reduction over time was associated with a lower rate of cardiovascular events compared with increasing or stable ET-1 (24.4% vs 50.0%).
Conclusions: ET-1 may be a unique predictor of HF prognosis, complementing other biomarkers in a multimarker profile. Serial measurement of ET-1 may provide additional prognostic information.
Circulating concentrations of the endogenous vasoconstrictor endothelin (ET) have been reported as elevated in patients with heart failure (HF), and the degree of ET elevation may be proportional to abnormalities in hemodynamics as well as HF symptom severity. [1] [2] [3] Some suggest that chronic activation of the ET system may lead to progression of left ventricular dysfunction as well as development of pulmonary hypertension. 4, 5 Accordingly, elevated ET levels may be associated with poor prognosis in patients with chronic HF. 6 There is evidence to suggest that activation of the ET system is closely tied to the neurohormonal activation in HF. 7 Indeed, the ET system appears to be a key player in vascular regulation through its action on the vascular smooth muscle cells, nitric oxide synthesis, and regulation of vascular tone; it has been closely associated with arterial and pulmonary hypertension, microvascular remodeling, and vascular stiffness, as well as cardiomyocyte hypertrophy and fibroblast proliferation. 2, 8 There are several known isoforms of ET. Of these, ET-1-a 21-amino acid vasoactive peptide with potent, dose-dependent vasoconstrictive properties-is the predominant form found in the cardiovascular (CV) system and has the most available data when it comes to prognosis in patients with chronic HF.
While a biomarker may provide interesting prognostic information in patients with HF, current understanding of the disease mechanism behind prognostication and clinical utility remains inadequate. 10, 11 For example, while ET-1 has been linked to pulmonary hypertension and prognosis in patients with HF with reduced ejection fraction (HFrEF), much is uncertain regarding mechanistic explanations for this finding. In addition, it is uncertain whether single measurement of ET-1 is sufficient for adequate prognostication or whether serial measurement adds to a single value. Moreover, individual and collective merit of ET-1 and other biomarkers of risk for patients with HFrEF is unknown. Accordingly, we set out to evaluate single and serial measurement of ET-1 in a well-characterized cohort of patients with HFrEF with available clinical and biochemical predictors of risk enrolled in the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study (clinicaltrials.gov NCT00351390). 12 We wished to better characterize patient characteristics associated with ET-1, explore ramifications of ET-1 elevation relative to cardiac structure and function in serial echocardiography, and explore the hypothesis that use of multiple biomarkers providing "orthogonal" biological information as well as serial ET-1 measurement would yield superior prognostication.
Materials and Methods

Study Design and Patient Population
This is a post hoc analysis from the PROTECT study, a randomized, controlled, single-center trial that examined 151 patients with left ventricular ejection fraction (LVEF) of 40% or less, New York Heart Association (NYHA) functional class of II or higher, and a history of HF decompensation within 6 months of enrollment whose goal was to evaluate N-terminal pro-B-type natriuretic peptide (NTproBNP)-guided HF management vs standard HF care over 10 months. 12, 13 The primary end point of the trial was total CV events, a composite outcome that included cardiac death, worsening HF (new or worsening symptoms/signs of HF requiring unplanned intensification of decongestive therapy), HF hospitalization, clinically significant ventricular arrhythmia, acute coronary syndrome, and cerebral ischemia. As reported, most end points were related to worsening HF, HF hospitalization, or CV death. All patients gave informed consent, and study procedures were approved by Partners Healthcare Institutional Review Board and in accordance with the Declaration of Helsinki. This trial was registered with clinicaltrials.gov as NCT00351390.
Study Procedures
A blood sample for routine laboratory tests and supplemental biomarker measurements were obtained at each clinic visit and centrifuged for 15 minutes, with plasma frozen at -80 C. As previously described, 13 medications were adjusted at each clinic visit to achieve guideline-derived HF therapy with or without NT-proBNP-guided care. Detailed medication history of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), b-blockers (BBs), and loop diuretics was obtained.
Biomarker Measurement
Plasma EDTA from each patient was obtained at each visit, processed, aliquoted, and frozen at -80 C. NTproBNP was measured using the fourth-generation Elecsys proBNP assays (Roche Diagnostics, Indianapolis, IN). ET-1 was measured using the preclinical, first-generation SgxHD ET assay (Singulex, Alameda, CA; coefficient of variation 7% at 1.2 pg/mL and 6% at 1.8 pg/mL). In addition, for the purposes of the present analysis, we also considered the concentrations of highly sensitive troponin I (hsTnI) using the Erenna cTnl Immunoassay (Singulex; coefficient of variation 4% at 9.1 pg/mL and 9% at 94.6 pg/mL) and soluble ST2 (sST2) using the highly sensitive, second-generation Presage ST2 assay (Critical Diagnostics, San Diego, CA; coefficient of variation 1.4%) and second-generation galectin 3 assay (BG Medicine, Waltham, MA; coefficient of variation 8.0% at 0.16 ng/mL and 6.7% at 10.0 ng/mL) .
Echocardiography
Transthoracic echocardiographic data including left atrial volume index (LAVi), left ventricular end-diastolic volume index, left ventricular mass index, left ventricular end-systolic volume index, LVEF, right ventricular EF (RVEF), and right ventricular systolic pressure (RVSP) were obtained at baseline and at the end of the study. All measures were evaluated by physicians blinded to treatment allocation or ET-1 status.
Statistical Analysis
Categorical variables between groups were compared using the v 2 test or Fisher exact test as appropriate, and continuous variables were compared using the Student t, MannWhitney U, or Kruskal-Wallis test as appropriate. Normally distributed continuous variables were summarized using mean 6 standard deviation, while in the context of nonnormality, medians (25th-75th percentile) were used. Repeated measures were analyzed using Wilcoxon tests. Correlations between biomarker values were assessed using Pearson or Spearman correlations as appropriate.
The median (4.67 pg/mL), 75th percentile (5.90 pg/mL) and a receiver operating characteristic curve-determined ET-1 value for the presence of CV events were considered as the potential cutoff point for a binary variable for ET-1. The best cutoff point for determining our main measure of timeto-first CV event for multimarker modeling turned out to be the 75th percentile ET-1 value (5.90 pg/mL), which was subsequently used for further modeling. "Response" of the biomarker was defined as achievement of a concentration at or below the 75th percentile value of 5.90 pg/mL, while "non-response" was defined as ET-1 more than 5.90 pg/mL. We defined a time-integrated "percent time in response" for ET-1 as the proportion of time with 5.90 pg/mL or less relative to the total time enrolled in the study.
To evaluate the role of baseline ET-1 measurement in predicting clinical outcomes in a multivariable analysis, time-to-first CV event estimates were calculated using a cumulative hazard method; this was chosen to optimize data with varying lengths of follow-up. Patients who did not experience any CV events were censored at the earlier of 1 year or the date last known to be event free. Traditional variables included in the base model consisted of age, sex, renal function as assessed by estimated glomerular filtration rate (eGFR) and the presence of NYHA class III or IV symptoms. Two other baseline characteristics were also considered for the base model: LVEF and PROTECT treatment allocation arms. However, they were not included in the final base model as inclusion of these variables did not add significant incremental information in a model limited by small sample size; there was redundant information included in LVEF and NYHA classification in our past analyses, and neither LVEF or treatment allocation arms were significant in univariate analysis. Biomarkers considered in the multimarker panel besides ET-1 included NT-proBNP, hsTnI, sST2, and galectin 3. Biomarkers were first treated as binary variables. Previously published biomarker cutoff points maximizing accuracy for each biomarker were used: more than 1,000 pg/mL for NT-proBNP, more than 10.9 pg/mL for hsTnI, more than 35 ng/mL for sST2, and more than 20 ng/mL for galectin 3.
12,14-16 The analysis was repeated using logarithm-transformed biomarkers as continuous variables.
To compare regression models directly, analyses were repeated but limited only to patients who had all available variables with listwise case deletion. Last, a stepwise, forward conditional model was determined. Comparison between survival curves was made using the log rank test. For the net reclassification improvement analysis (NRI), the outcome of interest was 1-year mortality. Baseline models included model 1 with age (continuous), sex (binary), eGFR (continuous), and class III or IV symptom severity (binary); model 2 contained all variables in model 1 plus dichotomous results for NT-proBNP, hsTnI, and sST2. To determine the incremental value of the new marker, the baseline models were evaluated with and without the dichotomously modeled ET-1. NRI was calculated using the category-free (or continuous) approach. 17 We chose the category-less NRI since it is the most objective and versatile measure of improvement in risk prediction. In addition, we used 999 bootstrap replications to estimate the 95% confidence intervals for NRI. In all statistical analyses, a two-tailed P value of .05 or less was considered to indicate statistical significance. All analyses were performed with SAS (versions 9.2 and 9.3; SAS Institute, Cary, NC) or PASW (version 22; SPSS, Chicago, IL) software.
Results
A total of 115 patients had ET-1 data available. Of these, 99 patients had at least two ET-1 measurements, and 66 patients had all covariates and biomarker results available, mainly limited by blood sample availability. There were a total of 551 ET-1 measurements during the study follow-up. There were a total of 160 CV events in the original cohort.
Baseline Characteristics
The study cohort was initially divided into two groups according to the median ET-1 value for the cohort (4.67 vs >4.67 pg/mL) in an exploratory analysis Table 1 . There were no statistically significant differences between the two groups in basic characteristics such age, sex, or race. There were no significant differences between proportions of patients included in the NT-proBNP-guided study arm. In general, patients above the median ET-1 value tended to have more advanced HF, as evidenced by a higher proportion of patients with NYHA class III and IV symptom severity (P ¼ .03) and the presence of jugular venous distension (JVD; P ¼ .02). Patients with above the median ET-1 were more likely to have a history of systemic arterial hypertension and less likely to have diabetes mellitus (P ¼ .007 and .04, respectively).
Considering echocardiographic measures as a function of ET-1, there were no significant differences in LVEF (27% vs 27%; P ¼ .83), but we did find that patients with higher ET-1 were more likely to have greater LAVi (37.8 vs 30.2 mL/m 2 ; P ¼ .01); in addition, those with higher ET-1 values had lower RVEF (41.0% vs 49.8%; P ¼ .006), with a correspondingly higher RVSP (45.9 vs 40.7 mm Hg; P ¼ .04). Consistent with a picture of more advanced HF, patients with above the median ET-1 value had higher median concentration of NTproBNP (2,570 vs 1,462 pg/mL; P ¼ .007).
Relative to treatment, a similar proportion of patients in both groups was taking ARBs, MRAs, BBs, and loop diuretics with one exception; a lower proportion of patients with elevated ET-1 values was taking ACE inhibitors at baseline (53.1% vs 76.0%; P ¼ .02). Similarly, patients with above the median ET-1 value tended to take lower median baseline doses of ACE inhibitors (2.5 vs 5.0 mg lisinopril-equivalent total daily dose; P ¼ .07) while there were no differences in the median baseline doses of BBs, ARBs, MRAs, and loop diuretics (data not shown).
Correlation of Baseline ET-1 Values With Baseline Echocardiographic Measures
When ET-1 was treated as a continuous variable, similar findings were seen as when ET-1 was treated as a binary variable above and below the median value. There was no significant correlation between ET-1 value and LVEF (Spearman q ¼ 0.02, P ¼ .90), a positive correlation between ET-1 value and LAVi (q ¼ 0.26, P ¼ .02) and RVSP (q ¼ 0.26, P ¼ .04), and an inverse correlation with RVEF (q ¼ -0.27, P ¼ .02). There was no significant relationship between ET-1 value and left ventricular mass (q ¼ 0.05, P ¼ .70).
Correlation of Baseline ET-1 Values Compared With Other Biomarkers
Logarithm of NT-proBNP had the strongest correlation with logarithm of ET-1 (Pearson r ¼ 0.52, P < .001). Correlation with logarithm of other baseline biomarkers was Values are presented as number (%), mean 6 SD, or median (25th-75th percentile).
weaker (hsTnI, r ¼ 0.40, P < .001; sST2, r ¼ 0.31, P < .001; galectin 3, r ¼ 0.28, P ¼ .006).
ET-1 Cutoff Values Predicting Time-to-First CV Event
Compared with the median cutoff value of 4.58 pg/mL (hazard ratio [HR], 1.85; 95% confidence interval [CI], 0.93-3.70; P ¼ .08), the 75th percentile ET-1 cutoff value of 5.90 pg/mL was superior in predicting time-to-first CV event in a model containing traditional variables (HR, 1.99; 95% CI, 1.01-3.93; P ¼ .05) and was used for subsequent Cox regression analysis for cumulative hazard.
Role of Baseline ET-1 Concentration in Multimarker Regression Models in the Prediction of Time-to-First CV Event
First, all baseline biomarkers were treated as binary variables with previously specified cutoff points Table 2 . 15 There was a significant difference in CV event-free survival in patients with a baseline ET-1 of 5.90 pg/mL or less compared with patients with a baseline ET-1 more than 5.90 pg/mL (P ¼ .002; Figure 1 ).
When any one biomarker was added to the model containing ET-1 and traditional variables (two biomarker panels), ET-1 was predictive of time-to-first CV event with a statistical significance or trend; one exception was when NTproBNP was added. However, compared with the same NTproBNP-containing model without ET-1 Table 3 , the model containing ET-1 improved the -2 log likelihood with near statistical significance (P ¼ .06 for change in the model when adding ET-1). With the exception of galectin 3, all other biomarkers added independent information to the model.
In three biomarker models with traditional variables plus ET-1, NT-proBNP and hsTnI, or ET-1, hsTnI, and sST2, ET-1 was a predictor in the proportional hazard models with a statistical significance or strong trends. As noted, adding ET-1 to comparable models with NT-proBNP improved the -2 log likelihood to near significance (when adding ET-1 to models, P ¼ .06 for the model containing NT-proBNP and hsTnI, P ¼ .07 for the model containing NT-proBNP and sST2). When all biomarkers were added in a single model, galectin 3 was no longer statistically significant (P ¼ .50) while there was a trend for significance for ET-1 (P ¼ .09). NT-proBNP, hsTnI, and sST2 remained independently predictive.
When modeling was limited only to patients with all variables available (Table 3 , n ¼ 66), a direct comparison between models was possible. In general, there was incremental improvement in models with the addition of each biomarker; the best model, as defined by the lowest -2 log likelihood value, was that with traditional variables as well as ET-1, NT-proBNP, hsTnI, and sST2. This four-biomarker panel with traditional risk factors-ET-1 (HR, 2.25; 95% CI, 0.86-5.89; P ¼ .09), NT-proBNP (HR, 7.36; 95% CI, 1.28-42.15; P ¼ .03), hsTnI (HR, 6.16; 95% CI, 1.89-20.03; P ¼ .003), and sST2 (HR, 3.67; 95% CI, 1.31-10.30; P ¼ .01)-appeared to provide the overall best fit (the lowest -2 log likelihood value of 139) while minimizing overfitting. In subsequent stepwise, forward conditional modeling with traditional variables, the final model included NT-proBNP, hsTnI, and sST2 only but with a worse -2 log likelihood value of 142 compared with 139 for best models described above. Next, all biomarkers were treated as logarithm-transformed continuous variables in determining time-to-first CV event proportional hazard analysis. Results are shown in the Table 4 . When used as a continuous variable, ET-1 was not as strongly predictive in multimarker models for time-to-first CV event as when used as a binary variable using a predetermined cutoff point.
Net Reclassification Improvement
In an NRI analysis, adding ET-1 to the baseline model 1 containing traditional clinical variables significantly improved reclassification (50.8%; 95% bootstrap CI, 12.6-88.2; P ¼ .02) with 65.5% of nonevents correctly reclassified (P < .0001) while 14.7% of events were insignificantly incorrectly reclassified (P ¼ .33). Similarly, adding ET-1 to the baseline model 2 (included traditional clinical variables as well as biomarkers NT-proBNP, hsTnI, and sST2) also significantly improved reclassification (84.9%; 95% bootstrap CI, 37.7-129; P ¼ .002). This was also mainly driven by reclassification of nonevents (65.8% of nonevents were correctly reclassified [P < .0001] while 19% of events were insignificantly incorrectly reclassified [P ¼ .39]).
Number of Elevated Biomarker Levels and CV Events
In a four-biomarker model with ET-1, NT-proBNP, hsTnI, and sST2, patients with an increasing number of elevated biomarkers had higher number of CV events as well as a higher proportion of patients with CV events ( Figure 2 ; P ¼ .02 and P < .001, respectively). Notably, none of the patients with normal concentration of all four biomarkers had CV events, while 100% of participants with all four elevated had CV events.
Change in ET-1 Over Time by Response Status and Outcomes
There was a significant correlation between baseline and final ET-1 values ( Figure 3 ; q ¼ 0.65, P < .001); this is somewhat lower than many other markers in this cohort, implying a degree of change from baseline to final measurement. These changes had clinical meaning; those whose ET-1 decreased over time from above 5.90 ng/mL to below this value had a lower rate of CV events compared with patients whose ET-1 values increased or remained stable (24.4% vs 50.0%; P ¼ .02).
When divided by a patient's ET-1 status at baseline and final visit, patients whose ET-1 values were above the cutoff value at both time points had the highest CV event rate (77.8%) followed by an intermediate CV event rate for patients who changed their ET-1 over time across the cutoff value (45.0% and 47.1%). Patients whose ET-1 values were below the cutoff value at both times had the lowest CV event rate (25.6%; overall Fisher exact P ¼ .02). We found a quantitative ET-1 reduction of 2.18 pg/mL to be required to predict a more benign outcome (odds ratio [OR], 0.15; 95% CI, 0.03-0.77; P ¼ .02).
Next, we considered all 551 ET-1 measurements over the duration of follow-up. Categorizing patients as "never" below 5.90 ng/mL, "sometimes" below 5.90 ng/mL, and "always" below 5.90 ng/mL Figure 4 , we observed decreasing numbers of patients with CV events across categories (81.8%, 47.5%, and 25.0% CV event rate, respectively; Fisher exact P ¼ .001).
Last, integrating all 551 values over a 10-month followup period, the percent time in response (percentage of time spent below the cutoff point of 5.90 pg/mL) was strongly predictive of lower CV events with or without adjustment for clinical variables (adjusted OR, 0.75; 95% CI, 0.62-0.91; P ¼ .003).
Changes in ET-1 and Medication Changes
In an exploratory analysis, there was a trend for a weak inverse correlation between absolute changes in ET-1 and changes in ACE inhibitor dose (Spearman q ¼ -0.19, P ¼ .07) while there was no suggestion of a significant correlation between ET-1 changes and BBs, ARBs, MRAs, or loop diuretics.
Changes in ET-1 Over Time and Echocardiographic Changes
There was a trend for a correlation between absolute changes in ET-1 and absolute changes in LAVi (Spearman CI, confidence interval; ET-1, endothelin 1; GFR, glomerular filtration rate; HR, hazard ratio; hsTnI, highly sensitive troponin I; NA, not applicable; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; sST2, soluble ST2.
a Cutoff values: ET-1 (>5.90 pg/mL), NT-proBNP (>1,000 pg/mL), hsTnI (10.9 pg/mL), and sST2 (>35 ng/mL). q ¼ 0.204, P ¼ .08) while there was no significant correlation between ET-1 changes and changes in RVSP or RVEF.
Discussion
In this report, we comprehensively describe the characteristics of patients with HFrEF as a function of ET-1 concentrations, examine echocardiographic and medication aspects of patients divided as such, and then carefully evaluate the role of ET-1 relative to clinical variables and other modern HF biomarkers in a multimarker panel. Importantly, we also examined the role of serial measurement of ET-1 in patients with chronic HF. We performed these analyses in a wellphenotyped cohort of patients with HF. We report three primary findings: (1) patients with elevated ET-1, in general, had a clinical picture more consistent with advanced HF (symptoms, examination findings, evidence of elevated left and/or right heart filling pressures on echocardiogram) despite similar systolic left ventricular functions and less optimized on ACE inhibitors compared with patients without elevated ET-1; (2) baseline ET-1 concentrations were a strong, independent predictor of CV events in a multimarker model that included the best established biomarkers as well as traditional clinical and biochemical variables; and (3) serial measurement of ET-1 imparts additive information to clinical variables and powerful contemporary biomarkers for HF prognosis.
In the current era of numerous candidate HF biomarkers showing prognostic promise, rigorous assessment of a novel biomarker above and beyond clinical risk factors and established biomarkers is necessary. In our multivariable analysis, we evaluated the role of ET-1 to predict risk for CV events in a model that included traditional clinical and biochemical baseline variables as well as a panel of established HF biomarkers that have recommendations for such use in current clinical practice guidelines. 18 An elevated ET-1 concentration was predictive of time-to-first CV event; the best model with ET-1 included traditional variables plus ET-1, NT-proBNP, hsTnI, and sST2. Galectin 3 did not contribute independent information in a multimarker panel containing sST2, consistent with expectations. 19 Despite gross oversimplification and overlap in categories, ET-1 is closely linked with neurohormonal activation, NT-proBNP with left ventricular stretch from volume or pressure overload, hsTnI with myocardial injury, 20 and sST2 with myocardial fibrosis and left ventricular remodeling. 21 In theory, we could have added many more biomarkers to our panel, representative of other pathways potentially involved in HF. However, we felt that the incremental return on adding less established biomarkers to the model given our sample size was not worth overfitting our model. In the multivariable Cox regression models, adding NT-proBNP to a model containing ET-1 rendered the latter weakly nonsignificant. One of the potential explanations for this could be that NT-proBNP provides redundant biological information as ET-1 since there was a significant correlation between ET-1 and NT-proBNP values. Both NT-proBNP and ET-1 have been closely linked to the neurohormonal activation in HF, potentially mediated by angiotensin II. 22 Another potential explanation for the weakly nonsignificant ET-1 value may be due to type II error from small sample size. When more patients were included in the analysis in general, as was done with pairwise case deletion, ET-1 was more likely to be significant. However, overall model fit improved when ET-1 was added to models containing NT-proBNP as well as other biomarkers. More important, in a reclassification analysis, adding ET-1 to the baseline model that included traditional variables as well as a multimarker panel including NT-proBNP, hsTnI, and sST2 significantly improved reclassification, mainly driven by reclassification of nonevents by low ET-1 values. In our analysis, lower ET-1 concentrations were associated with better general HF status such as better NYHA functional class or lower frequency of JVD, but similar results have been found in our analyses of NT-proBNP, hsTnI, and sST2. 12, 15, 16 Unique to our results for ET-1 was the finding of associations with arterial hypertension, elevated LAVi, and decreased RVEF. Given our results, lower ET-1 concentrations may correctly identify and reclassify patients by screening out patients with high-risk characteristics not already identified by NT-proBNP, hsTnI, and sST2. Those always above 5.90 ng/mL ("always" nonresponders) had the highest event rate, followed by partial responders and full responders (ET-1 5.9 pg/mL). Fisher exact test, P ¼ .001.
that included traditional variables as well as a multimarker panel is not new, 6 the evaluation of ET-1 in a multimarker panel that included very contemporary HF biomarkers is noteworthy. ET-1 is an integral part of the vascular regulatory system with potent vasoconstrictive and mitogenic properties in humans. 23 In the heart, myocardial ET-1 gene knockout mice have been shown to develop progressive systolic dysfunction and dilated cardiomyopathy with myocardial stress, 9 and chronic ET-1 stimulation has been associated with negative inotropic effect, myocardial and vascular fibrosis, and hypertrophy. 24, 25 ET-1 appears to play a key role in angiotensin II-induced cardiac hypertrophy and neurohormonal activation in HF. 7 Therefore, it is not surprising that ET-1 was a key component in a multimarker panel.
Interest in use of a multimarker panel providing distinct "orthogonal" information to create an individualized profile reflective of the HF biologic milieu has been gaining momentum in recent years. Such a panel may be used to assist in risk stratification of known patients with HF as described in this study. Taking a step further, in a concept similar to the way cancer treatment has been personalized based on a set of markers of risk, a multimarker profile of the patient with HF sets the stage for "precision medicine"
26 techniques aimed at a more individualized approach to care linked to each individual biomarker signature; a future where a specific medication titration may be prioritized if a biomarker result "guides" such a medication titration may be envisioned.
A strength of the PROTECT analysis is the availability of serial samples to evaluate sequential measurement of the various biomarkers we have analyzed. To our knowledge, this is the first study to examine serial measurement of ET-1 over time in patients with HFrEF. We found that a time-integrated model was strongly predictive of CV events. Second, the direction of change (increased, stable, or decreased) in ET-1 values over time was also predictive of clinical outcomes. These two findings imply that serial measurement may add to a single baseline value and raise the tempting hypothesis that if therapies specifically applied to those patients with an elevated ET-1 result in an indicated reduction in the biomarker, one might expect improvement in prognosis. While ET receptor antagonism in patients has had mixed results when used in patients with HF, 27, 28 the application of these agents in those specifically with elevated ET-1 values has not been evaluated and may be worth evaluating further.
We found that ET-1 may identify a subgroup of patients with HF with elevated left and right heart filling pressures and pulmonary hypertension despite comparable left-sided systolic function. The link with elevated LA filling pressures in patients with elevated ET-1 is novel, as is the trend for a correlation between a change in ET-1 and a change in LAVi over time, which raises the question as to whether ET-1 has a role in diastolic noncompliance. 29 In combination with ET-1's known association with arterial hypertension and vasoconstriction, this opens the door for prospective evaluation of ET-1 in patients with prominently diastolic left ventricular dysfunction or HF with preserved ejection fraction, a group with little prognostic and therapeutic options available. Another interesting exploratory finding is the interaction between ACE inhibitors and ET-1 concentrations seen in our analysis. Previous studies have linked ET-1's role in neurohormonal activation via angiotensin II. 22 It is tempting to speculate whether patients with elevated ET-1 may particularly benefit from ACE inhibitor administration, but a large, prospective study is needed to answer that question. There are several limitations to our study-most notably its small sample size, which may be an issue in performing multivariable analysis. However, when more cases were included in the analysis, the strength of ET-1 prediction consistently improved. In this extensively phenotyped cohort, we were able to bring together multiple facets of the patients' HF status and allow comprehensive exploration of the role of ET in patients with chronic HF. Another potential limitation is generalizability; our patient cohort was relatively young for an HF cohort and mostly white men, and the study was conducted in a tertiary care center. However, in building a multivariable model to predict CV outcomes, age, race, and sex were not found to be independent predictors. In any case, findings from this post hoc analysis should be confirmed in a larger prospective trial. We did not adjust our results for multiple comparisons; thus, some findings may have been via play of chance, but our findings are directionally consistent. As with any post hoc analysis, the primary aim of the PROTECT study was different from the main hypothesis of our analysis. However, based on data, our results were statistically significant and consistent in their findings. Our results should inform the basis of a larger prospective study.
In conclusion, ET-1 may be an important and unique predictor of HF prognosis, complementing other biomarkers well as a part of a multimarker profile, and serial ET-1 measurement appears to add value for predicting risk. Further studies are needed to better understand the role(s) played by ET-1 in HF evaluation and management.
